Pfizer Venture Investments

Founded 2004

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 99
Average round size
info
The average size of a deal this fund participated in
$37M
Portfolio companies 80
Rounds per year 5.82
Lead investments 17
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.28
Exits 36
Key employees 8

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Pfizer Venture Investments appeared to be the VC, which was created in 2004. The leading representative office of defined VC is situated in the New York. The fund was located in North America if to be more exact in United States. Pfizer Venture Investments seemed to be an CVC arrangement as part of the organization.

The increased amount of exits for fund were in 2016. Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Merus, Epic Sciences, TetraLogic Pharmaceuticals. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Therapeutics, Pharmaceutical.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Pfizer Venture Investments, startups are often financed by Roche Venture Fund, Atlas Venture, Three Arch Partners. The meaningful sponsors for the fund in investment in the same round are Lundbeckfonden Ventures, Sofinnova Partners, OrbiMed. In the next rounds fund is usually obtained by New Enterprise Associates, SR One, Rock Springs Capital.

We also calculated 8 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Pfizer Venture Investments:
Typical Co-investors
Pfizer Venture Investments is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Pfizer Venture Investments:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Palamon Capital Partners United Kingdom, London
H2 Ventures Australia, Sydney
The Beijing News China, Beijing
U.S. Cellular United States, Chicago
Biogen Idec United States, Weston
Bonnier Sweden, Stockholm
Access Technology Ventures United States, New York
Azimuth Opportunity United States, New York
Lee Equity Partners United States, New York
Updata Ventures Partners United States, Reston
Government of Singapore -
The Quercus Trust -
Redwood Technologies -
Ronin Capital United States, Chicago
Ningbo Xuri Lamp Decoration China, Xiangshan
YouStartIT by MITA Innovation Hub -
KiaOra Ventures India, Haryana
H2 Ventures Australia, Sydney
Ascent Capital Partners -
Nelson Canada Limited -
JD MRO China, Beijing

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Jnana

Biotechnology
Health Care
Therapeutics
1
$50M18 Aug 2021 United States, Boston

Artios Pharma

Biopharma
Biotechnology
Medical Device
1
$150M27 Jul 2021 United Kingdom, Cambridge

TRex Bio

Bioinformatics
Biopharma
Biotechnology
1
$59M22 Jun 2021 United States, South San Francisco

Palleon Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
1
$100M17 Sep 2020 United States, " United States"}

BioAtla

Biotechnology
Health Care
Medical
1
$72M15 Jul 2020 United States, San Diego

MISSION Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
1
$15M06 Jul 2020 United Kingdom, Cambridge

Bolt Biotherapeutics

Biotechnology
Health Care
Medical
Pharmaceutical
1
$93M01 Jul 2020 United States, Redwood City

4D Molecular Therapeutics

Biotechnology
Drug Discovery
Genetics
1
$75M16 Jun 2020 United States, " United States"}

Autobahn Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
1
$76M11 Jun 2020 United States, San Diego
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform

– Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, announced the closing of a $50m Series B financing.
– The financing was led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures.
– Proceeds from this financing will enable Jnana to progress its lead program for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform for the discovery of small molecule therapeutics for hard-to-drug targets.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Pfizer Venture Investments?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: